MedTrace Logo

Tenofovir Combination or Mono-therapy for MDR CHB

NCT03597633 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 236

Last updated 2018-07-24

No results posted yet for this study

Summary

Treatment of multidrug resistant (MDR) chronic hepatitis B (CHB) is still a challenging issue. Hence, the investigators will perform a multicenter prospective cohort study for the evaluation of tenofovir disoproxil fumarate (TDF)-based therapy for MDR CHB at real life settings.

Conditions

  • Chronic Hepatitis b With Multidrug Resistance

Sponsors & Collaborators

  • Yonsei University

    collaborator OTHER

  • CHA University

    collaborator OTHER

  • Soon Chun Hyang University

    collaborator OTHER

  • Chonbuk National University

    collaborator OTHER

  • Hallym University

    collaborator OTHER

  • Inje University

    collaborator OTHER

  • The Catholic University of Korea

    collaborator OTHER

  • Korea University

    lead OTHER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-01
Primary Completion
2018-12-31
Completion
2019-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03597633 on ClinicalTrials.gov